摘要
免疫检查点抑制剂(ICIs)治疗显著延长了恶性肿瘤患者的生存期,改善了生活质量,但同时出现了多种免疫相关性不良反应(irAEs)。ICIs所致免疫介导性肝损伤(IMH)的发生率呈上升趋势,但严重程度不一,为更早的确诊IMH并进行个体化诊疗,合理应用药物治疗改善患者预后。
Immune checkpoint inhibitors(ICIs)treatment significantly prolonged the survival period of patients with lung cancer,liver cancer,and malignant melanoma and other solid malignant tumors and improved the quality of life.But at the same time a variety of immune-related adverse reactions(irAEs)appeared.The incidence of immune-mediated liver injury(IMH)caused by ICIs is increasing but the severity is different.To diagnose IMH earlier and perform individualized diagnosis and treatment,it is necessary to have a reasonable application of drug treatment.
作者
崔童
孙莉
田应选
Cui Tong;Sun Li;Tian Yingxuan(Respiratory Medicine Department,Graduate School of Xi'an Medical University,Xi'an 710021,China;Respiratory Medicine Department,Shaanxi Provincial People's Hospital Geriatric Hospital,Xi'an 710068,China)
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2022年第5期619-623,共5页
Chinese Journal of Geriatrics
基金
科技部主动健康和老龄化科技应对国家重点研发计划课题(2018YFC2002100,2018YFC2002103)
陕西省人民医院拔尖人才支持计划(2021BJ-22)。
关键词
免疫检查点抑制剂
肝毒性
Immune checkpoint inhibitor
Hepatotoxicity
